Stem definition | Drug id | CAS RN |
---|---|---|
growth hormone derivatives | 5413 | 1338578-34-9 |
Molecule | Description |
---|---|
Synonyms:
|
Somapacitan-beco is a human growth hormone (hGH) analog. It binds to a dimeric GH receptor in the cell membrane of target cells resulting in intracellular signal transduction and a host of pharmacodynamic effects. Some of these pharmacodynamic effects are primarily mediated by insulin-like growth factor I (IGF-I) produced in the liver, while others are primarily a consequence of the direct effects of somapacitan-beco.
|
None
None
Date | Agency | Company | Orphan |
---|---|---|---|
March 31, 2021 | EMA | Novo Nordisk A/S | |
Aug. 28, 2020 | FDA | NOVO NORDISK INC |
None
None
None
None
Source | Code | Description |
---|---|---|
ATC | H01AC07 | SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES Somatropin and somatropin agonists |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Adult growth hormone deficiency | indication | 421684006 | |
Diabetic retinopathy | contraindication | 4855003 | DOID:8947 |
Malignant neoplastic disease | contraindication | 363346000 | DOID:162 |
None
None
None
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Growth hormone receptor | GPCR | Kd | 8.04 | SCIENTIFIC LITERATURE | DRUG LABEL |
ID | Source |
---|---|
D11194 | KEGG_DRUG |
8FOJ430U94 | UNII |
C4726770 | UMLSCUI |
JG5 | PDB_CHEM_ID |
CHEMBL3707290 | ChEMBL_ID |
129894493 | PUBCHEM_CID |
DB15093 | DRUGBANK_ID |
C000594654 | MESH_SUPPLEMENTAL_RECORD_UI |
018501 | NDDF |
898157004 | SNOMEDCT_US |
4042238 | VANDF |
4042239 | VANDF |
2557373 | RXNORM |
338169 | MMSL |
38779 | MMSL |
d09620 | MMSL |
C000718308 | MESH_SUPPLEMENTAL_RECORD_UI |
10019 | INN_ID |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
SOGROYA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0169-2030 | INJECTION, SOLUTION | 6.70 mg | SUBCUTANEOUS | BLA | 31 sections |
SOGROYA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0169-2030 | INJECTION, SOLUTION | 6.70 mg | SUBCUTANEOUS | BLA | 31 sections |
SOGROYA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0169-2035 | INJECTION, SOLUTION | 3.30 mg | SUBCUTANEOUS | BLA | 31 sections |
SOGROYA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0169-2035 | INJECTION, SOLUTION | 3.30 mg | SUBCUTANEOUS | BLA | 31 sections |
SOGROYA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0169-2037 | INJECTION, SOLUTION | 10 mg | SUBCUTANEOUS | BLA | 31 sections |